- Home
- FFC vs FLGT Comparison
FFC vs FLGT Comparison
Compare FFC & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- FLGT
- Stock Information
- Founded
- FFC 1983
- FLGT 2011
- Country
- FFC United States
- FLGT United States
- Employees
- FFC N/A
- FLGT N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- FLGT Medical Specialities
- Sector
- FFC Finance
- FLGT Health Care
- Exchange
- FFC Nasdaq
- FLGT Nasdaq
- Market Cap
- FFC 798.8M
- FLGT 697.3M
- IPO Year
- FFC N/A
- FLGT 2016
- Fundamental
- Price
- FFC $16.81
- FLGT $22.45
- Analyst Decision
- FFC
- FLGT Buy
- Analyst Count
- FFC 0
- FLGT 3
- Target Price
- FFC N/A
- FLGT $25.33
- AVG Volume (30 Days)
- FFC 164.1K
- FLGT 194.5K
- Earning Date
- FFC 01-01-0001
- FLGT 11-07-2025
- Dividend Yield
- FFC 6.79%
- FLGT N/A
- EPS Growth
- FFC N/A
- FLGT N/A
- EPS
- FFC N/A
- FLGT N/A
- Revenue
- FFC N/A
- FLGT $303,223,000.00
- Revenue This Year
- FFC N/A
- FLGT $15.19
- Revenue Next Year
- FFC N/A
- FLGT $10.58
- P/E Ratio
- FFC N/A
- FLGT N/A
- Revenue Growth
- FFC N/A
- FLGT 4.31
- 52 Week Low
- FFC $11.90
- FLGT $14.57
- 52 Week High
- FFC $14.96
- FLGT $24.64
- Technical
- Relative Strength Index (RSI)
- FFC 56.77
- FLGT 44.89
- Support Level
- FFC $16.52
- FLGT $23.15
- Resistance Level
- FFC $16.82
- FLGT $23.86
- Average True Range (ATR)
- FFC 0.15
- FLGT 0.69
- MACD
- FFC 0.01
- FLGT -0.14
- Stochastic Oscillator
- FFC 78.38
- FLGT 15.12
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.